Vectus Granted FDA Pre-IND Meeting Request for VB0004 in IPF

We are pleased to announce that the US FDA has granted our request for a pre-Investigational New Drug (pre-IND) Type B meeting, in which written responses regarding our proposed development program for VB0004 in Idiopathic Pulmonary Fibrosis will be tabled: https://lnkd.in/eddVvRJF

The FDA’s detailed responses are expected to be received by mid-November 2026.

In conjunction with our US Regulatory Agent, Cardinal Health Regulatory Services, we will now finalise and submit the meeting package to the FDA.